Home >> Oncology/Hematology >> Oncology/Hematology >> Baked Goods >> Technology & Media >>

Erbitux (Colorectal Cancer) - Forecast and Market Analysis to 2023

Published: Nov-2014 | Format: PDF | GlobalData | Number of pages: 56 | Code: MRS - 3105


GlobalData has released its new PharmaPoint Drug Evaluation report, “Erbitux (Colorectal Cancer) - Forecast and Market Analysis to 2023”. Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. In terms of targeted treatments, the metastatic CRC treatment landscape is mature, including the branded treatments Avastin (bevacizumab), Erbitux (cetuximab), and Vectibix (panitumumab), treatments that have extended the survival of metastatic patients compared to chemotherapy-only regimens. However, high unmet needs remain for the extension of survival of metastatic patients, and particularly those with KRAS mutation-positive disease, for whom the epidermal growth factor receptor (EGFR) inhibitors Erbitux and Vectibix are not recommended.

In February 2004, Eli Lilly/BMS/Merck KGaA’s Erbitux (cetuximab) became the first monoclonal antibody to be approved by the FDA for metastatic CRC. The recombinant chimeric IgG1 monoclonal antibody was the first of a novel class of antibodies that target the EGFR pathway. Overexpression of the epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) is frequent in CRC, where it contributes to activate genes that drive the cell cycle and mitosis. The binding of Erbitux to EGFR inhibits the downstream signaling of the receptor and hence reduces tumor progression and initiates cell cycle arrest.


- Overview of Colorectal Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Erbitux including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Erbitux for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and China.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Colorectal Cancer
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Erbitux performance
- Obtain sales forecast for Erbitux from 2013-2023 in top eight countries (the US, France, Germany, Italy, Spain, the UK, Japan and China)

Table of Contents

1 Table of Contents 5
1.1 List of Tables 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 13
3.2 Clinical Staging 14
3.3 Symptoms 15
4 Disease Management 17
4.1 Diagnosis and Treatment Overview 17
4.1.1 Screening and Diagnosis 17
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 20
4.1.3 Clinical Practice 24
5 Competitive Assessment 31
5.1 Overview 31
6 Erbitux (Cetuximab) 33
6.1 Overview 33
6.2 Efficacy 34
6.3 Safety 35
6.4 SWOT Analysis 36
6.5 Forecast 37
7 Appendix 38
7.1 Bibliography 38
7.2 Abbreviations 44
7.3 Methodology 47
7.4 Forecasting Methodology 47
7.4.1 Diagnosed Colorectal Cancer Patients 47
7.4.2 Percent Drug-Treated Patients 48
7.4.3 General Pricing Assumptions 48
7.4.4 Average Body Weight and Surface Area Across the 8MM 49
7.4.5 Individual Drug Assumptions 49
7.4.6 Generic Erosion 50
7.5 Primary Research - KOLs Interviewed for this Report 51
7.6 Primary Research - Prescriber Survey 52
7.7 About the Authors 53
7.7.1 Analyst 53
7.7.2 Global Head of Healthcare 54
7.8 About GlobalData 55
7.9 Disclaimer 55

List of Tables

Table 1: TNM and Staging Classification System for CRC 15
Table 2: Symptoms of Colorectal Cancer 16
Table 3: Treatment Guidelines for CRC 21
Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global Markets, 2013 22
Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global Markets, 2013 23
Table 6: Leading Treatments for CRC, 2014 32
Table 7: Product Profile — Erbitux 34
Table 8: Erbitux SWOT Analysis, 2014 36
Table 9: Global Sales Forecast ($m) for Erbitux, 2013-2023 37
Table 10: Average Body Weight and Surface Area Across the 8MM 49
Table 11: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 52

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)3495 View Pricing